Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of weekly TV-1106 versus daily Genotropin in children with growth hormone deficiency
2013-004468-69Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of albusomatropin and somatropin in growth hormone deficiency (GHD) (4 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Safety and tolerability. Started Feb 2014; status: terminated.
02
Drugs
albusomatropinsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2013-004468-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004468-69.